Primary regulatory, court, programme and government sources used in this document are listed below. Supplier programme pages establish published terms and workflows, not independently audited capacity or service performance. Source review does not constitute a complete litigation search, facility audit or 50-state legal opinion.
- FDA — GLP-1 compounding policy clarification, including April 1, 2026 update: https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- FDA — Drug Shortages database: https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm
- US Court of Appeals for the Fifth Circuit — No. 25-10758, revised September 1, 2026: https://www.ca5.uscourts.gov/opinions/unpub/25/25-10758.0.pdf
- FDA — Proposed exclusion from the 503B bulks list, April 30, 2026: https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
- FDA — Concerns with unapproved GLP-1 drugs: https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- FDA — Registered Outsourcing Facilities; retrieved table updated November 6, 2026: https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
- FDA — Compounding inspections, recalls and other actions: https://www.fda.gov/drugs/human-drug-compounding/compounding-inspections-recalls-and-other-actions
- FDA — Is It Really FDA Approved?: https://www.fda.gov/consumers/consumer-updates/it-really-fda-approved
- California State Board of Pharmacy — Licence verification: https://www.pharmacy.ca.gov/about/verify_lic
- FDA — Pharmacist DSCSA responsibilities: https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/pharmacists-utilize-dscsa-requirements-protect-your-patients
- FDA — Small-business-dispenser exemption letter, August 6, 2026: https://www.fda.gov/media/194424/download
- LillyDirect — Healthcare-provider FAQ: https://www.lilly.com/lillydirect/hcp/faq
- NovoCare — Healthcare-provider home-delivery information: https://www.novocare.com/hcp/delivery.html
- CMS — Medicare GLP-1 Bridge information for pharmacies: https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-pharmacies
- HHS — Business Associates Frequently Asked Questions: https://www.hhs.gov/hipaa/for-professionals/privacy/guidance/business-associates/index.html
- FDA — Outsourcing-facility registration questions and answers: https://www.fda.gov/drugs/human-drug-compounding/questions-and-answers-related-guidance-entities-considering-whether-register-outsourcing-facilities
- FDA — GLP-1 safety-labelling communication, November 9, 2026: https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential
Sources cited on this page
- fda.gov · Source 1 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- accessdata.fda.gov · Source 2 ↗https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm
- ca5.uscourts.gov · Source 3 ↗https://www.ca5.uscourts.gov/opinions/unpub/25/25-10758.0.pdf
- fda.gov · Source 4 ↗https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
- fda.gov · Source 5 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- fda.gov · Source 6 ↗https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
- fda.gov · Source 7 ↗https://www.fda.gov/drugs/human-drug-compounding/compounding-inspections-recalls-and-other-actions
- fda.gov · Source 8 ↗https://www.fda.gov/consumers/consumer-updates/it-really-fda-approved
- pharmacy.ca.gov · Source 9 ↗https://www.pharmacy.ca.gov/about/verify_lic
- fda.gov · Source 10 ↗https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/pharmacists-utilize-dscsa-requirements-protect-your-patients
- fda.gov · Source 11 ↗https://www.fda.gov/media/194424/download
- lilly.com · Source 12 ↗https://www.lilly.com/lillydirect/hcp/faq
- novocare.com · Source 13 ↗https://www.novocare.com/hcp/delivery.html
- cms.gov · Source 14 ↗https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-pharmacies
- hhs.gov · Source 15 ↗https://www.hhs.gov/hipaa/for-professionals/privacy/guidance/business-associates/index.html
- fda.gov · Source 16 ↗https://www.fda.gov/drugs/human-drug-compounding/questions-and-answers-related-guidance-entities-considering-whether-register-outsourcing-facilities
- fda.gov · Source 17 ↗https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential